[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589155":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":24,"responsibleParty":38,"collaborators":24,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":24,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":24,"overallStatus":63,"whyStopped":24,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":24},{"fullName":5,"class":6},"The First Affiliated Hospital of Zhengzhou University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NR","EXPERIMENTAL","experimental group: 600 mg\u002Fd of oral NR, NIAGEN for two months",[13],"Dietary Supplement: NR",{"label":15,"type":10,"description":16,"interventionNames":17},"Vit E","control group: 200 mg\u002Fd of oral Vitamin E for two months",[18],"Dietary Supplement: Vit E",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DIETARY_SUPPLEMENT","600 mg\u002Fd of oral NR for two months",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"200 mg\u002Fd of oral Vitamin E for two months",[15],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Qingling Yang, Ph.D.","CONTACT","+8666271879","qingling531@163.com",{"name":35,"role":31,"phone":36,"phoneExt":24,"email":37},"Mengchen Wang, Master","+86 66271879","wmc13949362871@163.com",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Qingling Yang","Associate Research Fellow","100589155","nr-vs-vitamin-e-in-enhancing-fertility-100589155",false,"NCT06950736","NR vs. Vitamin E in Enhancing Fertility","Nicotinamide Riboside vs. Vitamin E for Enhancing Fertility in Advanced Maternal Age: A Randomized Parallel Trial","NRVEERSAAM","Inclusion Criteria:\n\n1. Infertile women aged between 35 and 42 years;\n2. 0.1 ng\u002FmL \\\u003C= AMH \\\u003C= 1.1 ng\u002Fml;\n3. Pregnancy aids who plan to perform in vitro fertilization and embryo transfer (antagonist program);\n4. Bilateral ovaries are present;\n5. Patients who voluntarily signed the informed consent and agreed to be followed up according to the requirements of the study protocol.\n\nExclusion Criteria:\n\n1. Adenomyosis and uterine fibroids compression of uterine uterine line;\n2. Untreated bilateral hydrosalpinx;\n3. Uncured endometrial disease;\n4. Any pregnancy occurred within 3 months before screening;\n5. Patients with clinically significant abnormal cervical examination results within 3 months before screening;\n6. Use of fertility regulators (such as clomiphene citrate, GnRH, metformin or oral contraceptives) within 1 month before randomization;\n7. Use hormone drugs within 1 month before randomization;\n8. Patients with acute infection of urinary and reproductive system;\n9. Patients with major systemic diseases, endocrine or metabolic abnormalities that are not suitable to participate in this study, as judged by the investigator;\n10. According to the judgment of the investigator, the presence of uterus (such as submucosal uterine fibroids, intermural uterine fibroids larger than 3 cm or smaller than 3 cm but affecting uterine cavity morphology, untreated endometrial polyps, uterine adhesions, uterine malformations, and ASRM stage Ⅲ-Ⅳ endometriosis). Patients with clinically significant ovarian (e.g., polycystic ovaries, ovarian cysts \\> 4 cm, inability to retrieve eggs from both or one ovary) or adnexa (e.g., hydrosalpinx) abnormalities;\n11. Patients with unexplained abnormal uterine bleeding;\n12. Patients with a history of ovarian, breast, uterus, hypothalamus, pituitary and other malignant tumors;\n13. Receive donor egg or embryo preimplantation genetic screening\u002Fembryo preimplantation genetic diagnosis (PGS\u002FPGD);\n14. Known past or current thromboembolic disease;\n15. Have a known serious mental illness or fail to understand the purpose and methods of the clinical trial, or fail to comply with the study procedures;\n16. Patients with contraindications or allergic history to the use of GnRH-a, r-hFSH, hCGα, progesterone;\n17. Those who are addicted to alcohol, tobacco, drugs or drug abuse;\n18. Being exposed to teratogenic amounts of radiation, poisons and drugs and in the action period;\n19. Patients with liver function injury, that is, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were 2.5 times higher than the upper limit of normal values;\n20. Persons who are HIV or syphilis positive;\n21. Those with positive serum pregnancy tests;\n22. Other reasons why the researcher considers it inappropriate to participate in the study. Suffers from a disease that is not suitable for the present assisted reproductive technology or for the present pregnancy;\n23. Participants who had participated in other clinical trials within 3 months prior to screening.",true,"FEMALE","35 Years","42 Years",{"count":55,"type":56},60,"ESTIMATED","INTERVENTIONAL",[59],"NA","This randomized controlled trial enrolled women of advanced maternal age (≥35 years) undergoing ART, who were allocated to an intervention group (oral nicotinamide riboside, NR) or a control group (oral vitamin E, VitE) for a 2-month pre-ART intervention. The study systematically evaluated NR's regulatory effects on ovarian function and ART outcomes by measuring NAD+ levels in ovarian granulosa cells (GCs) and peripheral blood mononuclear cells (PBMCs), anti-Müllerian hormone (AMH) concentrations.",[62],"Infertility Female","NOT_YET_RECRUITING","2025-04-27",{"date":66,"type":67},"2025-04-30","ACTUAL",{"date":69,"type":56},"2025-05-05",{"date":71,"type":56},"2027-12-01",{"name":5,"class":6}]